Literature DB >> 20177726

Risk factors for mortality among patients with Stenotrophomonas maltophilia bacteremia in Tokyo, Japan, 1996-2009.

H Araoka1, M Baba, A Yoneyama.   

Abstract

Stenotrophomonas maltophilia is an important nosocomial pathogen, especially among immunocompromised patients. The objective of this study was to clarify the clinical characteristics, prognosis, and prognostic factors of patients with S. maltophilia bacteremia in Japan. The microbiology records of all patients with S. maltophilia bacteremia between January 1996 and April 2009 at Toranomon Hospital, Tokyo, Japan, were retrospectively reviewed. A total of 53 cases of bacteremia were identified. Thirty patients had an underlying hematological disorder, and 23 were receiving hematopoietic transplantation. The overall mortality rate was 51%. On univariate analysis, neutropenia (p < 0.01), the presence of a central venous catheter, and mixed infection with enterococci (p < 0.05) were significantly related to the mortality. Among these variables, neutropenia (p < 0.01) and mixed infection with enterococci (p < 0.05) were independent factors associated with mortality. In contrast, all eight patients in whom S. maltophilia was the etiologic agent of catheter-related infection survived following catheter removal. S. maltophilia is an important pathogen among immunocompromised patients, especially in the neutropenic phase or mixed infection with enterococci. If a central venous catheter was present at the onset of S. maltophilia bacteremia, the prompt removal of the catheter was important.

Entities:  

Mesh:

Year:  2010        PMID: 20177726     DOI: 10.1007/s10096-010-0882-6

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  10 in total

Review 1.  Stenotrophomonas maltophilia meningitis. Report of two cases and review of the literature.

Authors:  K A Papadakis; S E Vartivarian; M E Vassilaki; E J Anaissie
Journal:  J Neurosurg       Date:  1997-07       Impact factor: 5.115

2.  Clinical characteristics and prognostic factors of patients with Stenotrophomonas maltophilia bacteremia.

Authors:  Chung-Hsu Lai; Chih-Yu Chi; Hsin-Pai Chen; Te-Li Chen; Chorng-Jang Lai; Chang-Phone Fung; Kwok-Woon Yu; Wing-Wai Wong; Cheng-Yi Liu
Journal:  J Microbiol Immunol Infect       Date:  2004-12       Impact factor: 4.399

3.  Changing trends in etiology of bacteremia in patients with cancer.

Authors:  A Safdar; G H Rodriguez; M Balakrishnan; J J Tarrand; K V I Rolston
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-08       Impact factor: 3.267

4.  The clinical spectrum of stenotrophomonas (xanthomonas) maltophilia respiratory infection.

Authors:  S E Vartivarian; E J Anaissie; E N Kiwan; K A Papadakis
Journal:  Semin Respir Crit Care Med       Date:  2000       Impact factor: 3.119

5.  Outbreak of Stenotrophomonas maltophilia bacteremia in allogenic bone marrow transplant patients: role of severe neutropenia and mucositis.

Authors:  J A Labarca; A L Leber; V L Kern; M C Territo; L E Brankovic; D A Bruckner; D A Pegues
Journal:  Clin Infect Dis       Date:  2000-01       Impact factor: 9.079

Review 6.  Stenotrophomonas maltophilia endocarditis: a systematic review.

Authors:  Ijaz A Khan; Nirav J Mehta
Journal:  Angiology       Date:  2002 Jan-Feb       Impact factor: 3.619

7.  Bacteremia due to Stenotrophomonas maltophilia in patients with hematologic malignancies.

Authors:  A Micozzi; M Venditti; M Monaco; A Friedrich; F Taglietti; S Santilli; P Martino
Journal:  Clin Infect Dis       Date:  2000-10-04       Impact factor: 9.079

8.  Risk factors for Stenotrophomonas maltophilia bacteremia in oncology patients: a case-control study.

Authors:  Anucha Apisarnthanarak; Jennie L Mayfield; Teresa Garison; Patricia M McLendon; John F DiPersio; Victoria J Fraser; Louis B Polish
Journal:  Infect Control Hosp Epidemiol       Date:  2003-04       Impact factor: 3.254

9.  Bacteraemia due to Stenotrophomonas maltophilia: an analysis of 45 episodes.

Authors:  N D Friedman; T M Korman; C K Fairley; J C Franklin; D W Spelman
Journal:  J Infect       Date:  2002-07       Impact factor: 6.072

10.  Polymicrobial septicemia in the cancer patient.

Authors:  L S Elting; G P Bodey; V Fainstein
Journal:  Medicine (Baltimore)       Date:  1986-07       Impact factor: 1.889

  10 in total
  25 in total

1.  Antibiotics resistance of Stenotrophomonas maltophilia strains isolated from various clinical specimens.

Authors:  Aytekin Çıkman; Mehmet Parlak; Yasemin Bayram; Hüseyin Güdücüoğlu; Mustafa Berktaş
Journal:  Afr Health Sci       Date:  2016-03       Impact factor: 0.927

2.  Risk factors influencing mortality related to Stenotrophomonas maltophilia infection in hematology-oncology patients.

Authors:  Hayati Demiraslan; Mustafa Sevim; Çiğdem Pala; Süleyman Durmaz; Veli Berk; Leylagül Kaynar; Gökhan Metan
Journal:  Int J Hematol       Date:  2013-02-22       Impact factor: 2.490

3.  Extracellular enzyme profiling of Stenotrophomonas maltophilia clinical isolates.

Authors:  Renjan Thomas; Rukman Awang Hamat; Vasanthakumari Neela
Journal:  Virulence       Date:  2014-01-21       Impact factor: 5.882

Review 4.  Stenotrophomonas maltophilia: an emerging global opportunistic pathogen.

Authors:  Joanna S Brooke
Journal:  Clin Microbiol Rev       Date:  2012-01       Impact factor: 26.132

5.  Alterations of lung microbiota in a mouse model of LPS-induced lung injury.

Authors:  Valeriy Poroyko; Fanyong Meng; Angelo Meliton; Taras Afonyushkin; Alexander Ulanov; Ekaterina Semenyuk; Omar Latif; Vera Tesic; Anna A Birukova; Konstantin G Birukov
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2015-05-08       Impact factor: 5.464

Review 6.  Clinical challenges treating Stenotrophomonas maltophilia infections: an update.

Authors:  Maria F Mojica; Romney Humphries; John J Lipuma; Amy J Mathers; Gauri G Rao; Samuel A Shelburne; Derrick E Fouts; David Van Duin; Robert A Bonomo
Journal:  JAC Antimicrob Resist       Date:  2022-05-05

Review 7.  Achromobacter xylosoxidans and Stenotrophomonas maltophilia: Emerging Pathogens Well-Armed for Life in the Cystic Fibrosis Patients' Lung.

Authors:  Quentin Menetrey; Pauline Sorlin; Estelle Jumas-Bilak; Raphaël Chiron; Chloé Dupont; Hélène Marchandin
Journal:  Genes (Basel)       Date:  2021-04-21       Impact factor: 4.096

8.  Stenotrophomonas maltophilia infections in a general hospital: patient characteristics, antimicrobial susceptibility, and treatment outcome.

Authors:  George Samonis; Drosos E Karageorgopoulos; Sofia Maraki; Panagiotis Levis; Dimitra Dimopoulou; Nikolaos A Spernovasilis; Diamantis P Kofteridis; Matthew E Falagas
Journal:  PLoS One       Date:  2012-05-18       Impact factor: 3.240

9.  Stenotrophomonas maltophilia: Complicating treatment of ESBL UTI.

Authors:  Simit Kumar; Maitreyi Bandyopadhyay; Mitali Chatterjee; Parthajit Banerjee; Sumon Poddar; Debarati Banerjee
Journal:  Adv Biomed Res       Date:  2015-02-11

10.  Risk Factors Associated with Stenotrophomonas maltophilia Bacteremia: A Matched Case-Control Study.

Authors:  Kosuke Sumida; Yong Chong; Noriko Miyake; Tomohiko Akahoshi; Mitsuhiro Yasuda; Nobuyuki Shimono; Shinji Shimoda; Yoshihiko Maehara; Koichi Akashi
Journal:  PLoS One       Date:  2015-07-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.